Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

BMS has reported that the Phase II TRANSCEND FL trial assessing Breyanzi, met its primary endpoint in the marginal zone ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Radiopharm Theranostics’ RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate MZE829, in treating subjects with AKD ...

Lilly has revealed that subjects with Crohn's disease have achieved long-term clinical and endoscopic outcomes with Omvoh in the VIVID-2.

Early detection and public health interventions are critical in improving sepsis survival rates and limiting its long-term ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

The partnership between the US military and the body and the non-profit will examine three drugs as potential therapies ...

MSD has commenced the Phase III trial to assess zilovertamab vedotin combined with R-CHP to treat individuals with previously ...